Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM75EAT)

Drug Name

(4-Fluoro-phenyl)-(9H-purin-6-yl)-amine Drug Info

Synonyms

73663-95-3; N-(p-Fluorophenyl)adenine; (4-Fluorophenyl)(9H-purin-6-yl)amine; NSC 21554; N-(4-fluorophenyl)-9H-purin-6-amine; 7H-ADENINE, N-(p-FLUOROPHENYL)-; N-(4-fluorophenyl)-7H-purin-6-amine; 1H-Purin-6-amine, N-(4-fluorophenyl)-; CHEMBL361227; N-(4-Fluorophenyl)-1H-purin-6-amine; W-203680; (4-Fluoro-phenyl)-(9H-purin-6-yl)-amine; AC1L1C3G; 6-(4-Fluoroanilino)purine; Oprea1_396984; SCHEMBL4922514; N-(p-Fluorophenyl)-1H-adenine; CTK5D8432; (4-fluorophenyl)purin-6-ylamine; DTXSID30223881; MolPort-000-384-310; NSC21554

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 51998
CAS Number: CAS 73663-95-3
TTD Drug ID: DM75EAT

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Rho-associated protein kinase 1 (ROCK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Netarsudil	DM0LPI9	Open-angle glaucoma	9C61	Approved	[2]
SAR-407899	DMF95KD	Diabetic nephropathy	GB61.Z	Phase 2	[3]
H-1152	DM8XH3S	Pulmonary arterial hypertension	BB01.0	Phase 2	[4]
INS-117548	DMA46DO	Glaucoma/ocular hypertension	9C61	Phase 1	[5]
GSK269962A	DM5I2HL	Inflammation	1A00-CA43.1	Clinical trial	[6]
PMID28048944-Compound-19	DMPT3V9	N. A.	N. A.	Patented	[7]
PMID28048944-Compound-3	DM1BN74	N. A.	N. A.	Patented	[7]
PMID28048944-Compound-7	DMXZ368	N. A.	N. A.	Patented	[7]
PMID28048944-Compound-4	DMJAUWG	N. A.	N. A.	Patented	[7]
PMID28048944-Compound-5	DMAB987	N. A.	N. A.	Patented	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Rho-associated protein kinase 1 (ROCK1)	TTZN7RP	ROCK1_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.
2	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
3	The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries. J Hypertens. 2012 May;30(5):980-9.
4	Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
5	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
6	Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98.
7	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.